Kornimate/medical-research-clean huggingface dataset:
data and sample collection study to elucidate the mechanisms of eosinophilic disorders

Conditions: Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease; Food Allergy

Summary: the purpose of this study is to elucidate the mechanisms underlying eosinophil growth, survival, migration, and function and to investigate and further characterize the pathophysiology of, clinical manifestations of, and spectrum of disease severity of eosinophilic inflammation in humans.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained from the patient or parent/guardian. assent will be obtained from all minors 11 years of age and older. * carrying a diagnosis of eosinophilic gastrointestinal disease, eosinophilic inflammatory disease, or food allergy or family member, or normal control

Keywords: eosinophilic disorders
dha-paclitaxel in treating patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of dha-paclitaxel in treating patients who have metastatic colorectal cancer.

objectives: i. determine the objective tumor response rate, duration of response, and time to disease progression in patients with metastatic colorectal cancer treated with dha-paclitaxel. ii. determine the overall survival of patients treated with this drug. iii. determine the toxicity profile of this drug in these patients. iv. assess the quality of life of patients treated with this drug. outline: this is a multicenter study. patients receive dha-paclitaxel iv over 2 hours on day 1. treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. quality of life is assessed at baseline, every 2 courses, and at end of study treatment. patients are followed every 3 months. projected accrual: a total of 18-50 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed cancer of the colon or rectum clinical evidence of metastatic disease failed 1 prior chemotherapy regimen for metastatic disease measurable disease no known or clinical evidence of cns metastasis patient characteristics: age: 18 and over performance status: ecog 0-1 life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) sgot or sgpt no greater than 2.5 times uln renal: creatinine no greater than 1.5 times uln cardiovascular: no uncontrolled ventricular arrhythmia no myocardial infarction within the past 3 months no superior vena cava syndrome neurologic: no peripheral neuropathy greater than grade 1 no uncontrolled major seizure disorder no spinal cord compression other: no unstable or serious concurrent medical condition no concurrent serious infection requiring parenteral therapy no other prior malignancy except: curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix or other cancer curatively treated with surgery alone that has not recurred for more than 5 years no psychiatric disorder that would preclude study not pregnant or nursing negative pregnancy test fertile patients must use effective contraception during and for 6 months after study prior concurrent therapy: biologic therapy: no concurrent immunotherapy chemotherapy: see disease characteristics no more than 1 prior chemotherapy regimen for metastatic disease no prior taxanes at least 28 days since prior chemotherapy and recovered no other concurrent chemotherapy endocrine therapy: no concurrent hormonal therapy radiotherapy: at least 28 days since prior large-field radiotherapy and recovered no concurrent radiotherapy surgery: at least 14 days since prior major surgery and recovered

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer
the impact of treating minor uterine cavity abnormalities diagnosed by office hysteroscopy in unselected in vitro fertilization (ivf) cases

Conditions: Minor Intra-uterine Abnormalities

Summary: this is a comparative, controlled trial to evaluate the impact of treating undetected, asymptomatic, predefined minor uterine cavity abnormalities on the success of ivf treatment.

introduction- implantation failure after ivf may be due to endometrial function, embryo quality or a combination of both. the prevalence of minor intracavitary pathology in cases with an apparent normal transvaginal sonography (tvs) observed at hysteroscopy has been recorded to be 25-40%. treatment of such pathology prior to initiating ivf/icsi has been advocated without high-quality evidence. objective- to evaluate the impact of treating undetected, asymptomatic, predefined minor uterine cavity abnormalities on the success of ivf treatment. material \& methods- patients, indicated for their first ivf/icsi treatment cycle at the umc utrecht and az-vub brussels, initially underwent tvs. in case of a normal tvs these patients were scheduled for hysteroscopy in the early-mid follicular phase of the cycle, one to three months before starting ivf/icsi treatment. vaginoscopic hysteroscopy was performed in an ambulatory office setting. during the hysteroscopy a biopsy was taken, to diagnose chronic endometrial inflammation. in case of finding a predefined intra uterine abnormality (polyp, myoma, adhesion, septum, endometrial inflammation) randomisation took place if prior to hysteroscopy informed consent had been obtained for endoscopy treatment versus no treatment. shortly after the hysteroscopy, ivf/icsi treatment was initiated and outcome during one year treatment period will be recorded.

Eligibility criteria:
inclusion criteria: * normal transvaginal ultrasound * no prior hysteroscopy * regular menstrual cycle * single embryo transfer * bmi between 18 and 29 * presence of both ovaries * primary or secondary infertility * women indicated for a first ivf/icsi cycle exclusion criteria: * recurrent miscarriage * prior hysteroscopic treatments * endometriosis \> afs stage ii * meno-metrorrhagia (defined as any intermenstrual loss of blood) * submucosal/intracavitary fibroids taking more than 50% of the cavity * hydrosalpinx * fsh/lh \> 12iu/l on day 3 * polyps taking more than 50% of the cavity * severe adhesions \> grade ii

Keywords: intra-uterine abnormalities intracavitary pathology hysteroscopy ivf icsi polyp myoma adhesion septum endometritis
fulminant severe cap - an observational study

Conditions: Community-acquired Pneumonia; Severe Pneumonia; ARDS, Human; Sepsis

Summary: severe community-acquired pneumonia (cap) represents a major cause of hospital mortality. among severe cap cases, some exhibit a rapidly progressive evolution, leading to severe ards/acute respiratory failure and septic shock within hours to a few days. this type of pneumonia, known as "fulminant pneumonia," is characterized by its rapid onset and deterioration, often necessitating immediate medical intervention. despite its severity, the true incidence and optimal treatment for fulminant pneumonia are not well understood. this knowledge gap is due to the lack of attention towards pneumonia as a potential time-dependent illness and the separation of overlapping clinical topics: severe pneumonia, ards, and sepsis. in clinical practice, pneumonia is the most frequent cause of both ards and sepsis. however, these conditions are often considered separately, combining ards and sepsis from various extra-pulmonary causes with those originating from pneumonia. the covid-19 pandemic, with its vast number of severe cap cases in a short period, has highlighted the existence of fulminant pneumonias, underscoring the need for further investigation. recent randomized clinical trials (rcts) and experiences from covid-19 have suggested that early and prolonged corticosteroid administration can reduce mortality in patients with severe sars-cov-2 infection and severe cap/ards of bacterial origin. the aim of this observational study is to analyze the rate of fulminant pneumonia and assess the impact of early corticosteroid treatment in a multicentric population of hospitalized patients with severe pneumonia.

a list of consecutive patients with severe cap from the 5 participating centers from january 2018 to july 2024. patients recruited for concomitant randomized clinical trials were allowed. each center used an early antibiotic policy (\<6 hours) in case of sepsis and/or severe pneumonia diagnosis. the use of corticosteroids varied from several reasons (e.g. rct protocol, internal policy, physician on duty with not restriction to this. both covid and non-covid patients were recruited if pao2:fio2 \ 99mg/l, respiratory rate\>25bpm or signs of respiratory distress, need for respiratory support (cpap, mv, hfnc), creatinine\>1,49mg/dl, alt\>70. hospital-acquired and healthcare-acquired pneumonia were excluded. also, chronic end-stage illness (e..g. metastatic cancers, advanced neuromuscolar disorders, etc) were excluded. the following patient caractheristics and clinical data were collected at admission: oxygenation state, vital signs, age, type of unit at admission, admission to icu, length of hospital stay, type and duration of mechanical ventilation (mv), initial and maximal peep administered, alt, wbc, platelets, haemoglobin, presence of obesity, comorbidities, risk factors (smoking, abuse).

Eligibility criteria:
inclusion criteria: severe community acquired pneumonia according to ats/idsa - exclusion criteria: incomplete outcome data -

Keywords: fulminant pneumonia community acquired pneumonia ards sepsis corticosteroids
maintenance of efficacy.

Conditions: Fibromyalgia

Summary: the hypothesis of study a6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.


Eligibility criteria:
inclusion criteria: * subjects must meet the american college of rheumatology (acr) criteria for fibromyalgia * pain score greater than or equal to 4 on an 11-point nrs * fiq-total score greater than or equal to 45 points exclusion criteria: * other severe pain that may confound assessment or self evaluation of the pain associated with fibromyalgia * any autoimmune rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), clinically significant active infection, or untreated endocrine disorder * uncontrolled hypertension pending worker's compensation; current or recent diagnosis or episode of major depressive disorder, dysthymia and/or uncontrolled depression; subjects to be at risk of suicide;

Keywords: double-blind placebo-controlled maintenance of efficacy
hbot for patients with ic/fm (interstitial cystitis/fibromyalgia)

Conditions: Fibromyalgia; Interstitial Cystitis

Summary: the investigators observed 12 fibromyalgia and interstitial cystitis patients undergoing hyperbaric oxygen oxygen treatment in a multiplace pressure chamber for 90 minutes, 40 treatment each, using an oro-nasal mask.

the investigators structured a prospective observational pilot experimental design in consenting patients with ic and fm, with repeated subjective and urological measures conducted before and after a therapeutic protocol. the study duration was set to 3 months. patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ata) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask. patients undertook a cycle of 20 sessions for 5 days per week for four weeks. after one week of suspension, a second cycle of 20 sessions was completed.

Eligibility criteria:
inclusion criteria: * presence of absence of hunner's ulcers * pain in bladder that improves with urination * pain(supra-pubic, pelvic, urethral, vaginal, or perineal) * presence of glomerulation or bleeding +/- at the cystodistension * reduced capacity * increased proprioceptive sensitivity * normal or reduced compliance * number of tender points that establish that diagnosis exclusion criteria: * pregnancy (diagnosed or within a year) * age less than 18 years * benign or malignant bladder tumors * radiation cystitis * symptomatic bladder diversions * herpes in active phase * bladder and urethral stones * urinary frequency less than 10 times a day * presence of symptoms less than 12 months * bladder capacity\>400ml with no sensitive urgency
postoperative music for orbital decompression

Conditions: Surgery; Pain; Musth

Summary: the purpose of this study is to evaluate the effect of music to the postoperative pain and discomfort after orbital decompression.

to investigate the effect of music to the postoperative pain and discomfort after orbital decompression under general anesthesia.

Eligibility criteria:
inclusion criteria: * 16-75 years old * diagnosed as thyroid eye disease * bone removal orbital decompression under general anesthesia exclusion criteria: * any uncontrolled clinical problems * orbital decompression under local anesthesia * reluctance to participate in clinical trials

Keywords: postoperative pain postoperative discomfort general anesthesia
d-tecting disease - from exposure to vitamin d during critical periods of life

Conditions: Vitamin D Deficiency; Obesity; Diabetes Mellitus; Pre-Eclampsia; Arthritis; Asthma; Bone Fracture; Tooth Diseases; Birth Weight; Birth Disorder; Pregnancy Complications; Mental Disorder; Cancer; Congenital Disorders

Summary: vitamin d deficiency is common among otherwise healthy pregnant women and may have consequences for them as well as the early development and long-term health of their children. however, the importance of maternal vitamin d status has not been widely studied. the present study is divided into a societal experiment (1) and a case-cohort study (2): 1. the present study includes an in-depth examination of the influence of exposure to vitamin d early in life and during critical periods of growth for development of type 1 diabetes (t1d), type 2 diabetes, gestational diabetes, pre-eclampsia, obesity, asthma, arthritis, cancer, mental and cognitive disorders, congenital disorders, dental caries and bone fractures during child- and adulthood. the study is based on the fact that mandatory fortification of margarine with vitamin d, which initiated in 1937, was terminated in 1985. apart from determining the influences of exposure prior to conception and during pre- and postnatal life, the investigators examined the importance of vitamin d exposure during specific seasons and trimesters, by comparing disease incidence among individuals born before and after the fortification. 2. additionally, a validated method was used to determine neonatal vitamin d status using stored dried blood spots (dbs) from individuals who develop the aforementioned disease entities as adults and their time and gender-matched controls. unparalleled, the study will help determine the effects of vitamin d exposure during critical periods in life. there are a sufficient number of individuals to verify any effects during different gestation phases and seasons of the year. the results, which will change our current understanding of the significance of vitamin d, will enable new research in related fields, including interventional research designed to assess supplementation needs for different subgroups of pregnant women. also, other health outcomes can subsequently be studied to generate multiple new interdisciplinary health research opportunities involving vitamin d.


Eligibility criteria:
inclusion criteria: 1. born in denmark around the fortification period 2. sufficient amount of blood from the dbs exclusion criteria: 1.born outside denmark 1. born outside the fortification period 2. insufficient amount of blood from the dbs or dbs not found
the correlation of periostin and renal pathology in chronic kidney disease patients

Conditions: Lupus Nephritis; IgA Nephropathy

Summary: the purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and iga nephropathy.

total of 50 lupus nephritis and iga nephropathy patients who met the inclusion criteria were included in this study. the information sheet and informed consent will be obtained before collecting the patient's data. all patients were interviewed for collecting demographic data and laboratory testing were reviewed from patient's record. kidney tissue and urine sample were collected at the biopsy date from patients.kidney tissue were stained with hematoxylin and eosin (h\&e), masson's trichrome solution and immunohistochemistry for periostin. the location of periostin staining in kidney tissue were assessed by renal pathologist. the total of 50 urine samples from patients and 50 urine samples from healthy controls were measured for periostin level by enzyme-linked immunosorbent assay. the mann-whitney rank-sum test was used for comparing urine periostin level between patients and healthy controls and also other variables between patients with urine periostin detection and without urine periostin detection. spearman correlation coefficients were used test correlations between urine periostin level in patients and other variables. receiver operating characteristic curves was generated to calculate the area under the curve and find the best cutoff value of urine periostin level for distinguishing patients from healthy controls. p-values \< 0.05 were considered statistically significant.

Eligibility criteria:
inclusion criteria: * aged over 18 years * at least three glomeruli obtained at biopsy exclusion criteria: * patients with urinary tract obstruction * patients with urinary tract infection * patients with kidney transplant * patients with cancer diseases * patients with asthma * patients with advanced heart disease * pregnancy and lactation

Keywords: periostin staining urine periostin level lupus nephritis iga nephropathy
detection of early esophageal cancer by nir-fme.

Conditions: Barrett Esophagus

Summary: to improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in barrett's esophagus (be), there is a need for better endoscopic visualization and the ability for targeted biopsies. optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. it is known that the biomarker vascular endothelial growth factor (vegf) is overexpressed in dysplastic and neoplastic areas in be segments versus normal tissue and has proven to be a valid target for molecular imaging. the university medical center groningen (umcg) developed a fluorescent tracer by labeling the vegf-targeting humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the fluorescent dye irdye800cw. the phase i study, named vice, completed within the umcg, showed that synchronal use of vegfa-guided near-infrared fluorescence molecular endoscopy (nir-fme) and high-definition white light endoscopy (hd-wle), following topical or systemic tracer administration, could be practiced to recognize dysplastic and early eac lesions in patients with be. furthermore, early lesion detection was improved by \~33% using the topically applied tracer approach compared with hd-wl/nbi endoscopy. with this phase 2 intervention study the investigators aim to statistically confirm previous pilot (phase i) clinical data showing that the combination of hd-wle and fme using labelled bevacizumab improves early ec detection over the current clinical standard.

see brief summary

Eligibility criteria:
inclusion criteria: * suspicion or diagnosed lgd, hgd or superficial eac and planned diagnostic and/or therapeutic endoscopy. * age: 18 years or older. * written informed consent. exclusion criteria: * patients younger than 18 years old * submucosal and invasive eac; eac with tnm-classification other than t1. * radiation therapy for esophageal cancer * immunoglobulin allergy * chemotherapy, immunotherapy or surgery 28 days before administration of the tracer * prior bevacizumab treatment * non-adjustable hypertension * medical or psychiatric conditions that compromise the patient's ability to give informed consent. * pregnancy or breast feeding.

Keywords: fluorescence endoscopy bevacizumab-800cw
evaluation of transconjunctival approach in management of orbital tumors

Conditions: Orbital Tumors

Summary: many surgical approaches for excision of orbital tumors have been described. these approaches do not allow access to all orbital quadrants. furthermore, some of these approaches are technically difficult, associated with long morbidity and post operative pain, having high rate of complications or having unacceptable cosmetic appearance. the investigators present the transconjunctival approach as an alternative procedure that allows access to orbital tumors in different locations as well as less morbidity and better cosmetic results

orbital tumors are divided anatomically into intraconal and extraconal depending on their relationship with the muscle cone which is further classified into anterior and posterior orbital tumors. excision of orbital tumors is considered a challenge for the surgeon. this is due to the complex structure of the orbit. the orbital cavity is narrow that does not allow adequate exposure. furthermore, the orbit is full of vital structures which require careful manipulation. many surgical approaches for excision of these tumors have been described. these approaches do not allow access to all orbital quadrants. furthermore, some of these approaches are technically difficult, associated with long morbidity and post operative pain due to the osteotomy, having high rate of complications or having unacceptable cosmetic appearance. few studies with limited number of patients have used transconjunctival approach in management of orbital tumors all patients with orbital tumor will be managed by the transconjunctival incisional or excisional biopsy according to the suggested nature of the tumor being benign or malignant as well as the site of the tumor using the clinicoradiological finding. in case of intraconal tumors, the mass will be approached via the transconjunctival approach but if the mass is out of reach via this approach, lateral orbitotomy approach will be used as an alternative procedure to perform the predetermined decision. this allows detection of the intraconal tumor criteria that could be excised safely via this approach

Eligibility criteria:
inclusion criteria: * patients with orbital tumor either benign or malignant. exclusion criteria: * patients with apical tumors not accessible with transconjunctival approach. * patients with too anterior tumors (superficial dermoid and lacrimal gland swelling). * patients with non-neoplastic orbital lesions. * patients with follow up period of less than 3 months

Keywords: orbital tumors transconjunctival approach